The estimated Net Worth of Equity Opportunities Fund I... is at least $379 Million dollars as of 8 April 2019. Equity I owns over 4,347,827 units of AVEO Pharmaceuticals Inc stock worth over $378,657,975 and over the last 8 years Equity sold AVEO stock worth over $0.
Sign up
Equity I AVEO stock SEC Form 4 insiders trading
Equity has made over 15 trades of the AVEO Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Equity bought 4,347,827 units of AVEO stock worth $4,956,523 on 8 April 2019.
The largest trade Equity's ever made was buying 6,000,000 units of AVEO Pharmaceuticals Inc stock on 28 March 2017 worth over $3,000,000. On average, Equity trades about 992,078 units every 49 days since 2017. As of 8 April 2019 Equity still owns at least 25,243,865 units of AVEO Pharmaceuticals Inc stock.
You can see the complete history of Equity I stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at AVEO Pharmaceuticals Inc
Over the last 15 years, insiders at AVEO Pharmaceuticals Inc have traded over $6,664,465 worth of AVEO Pharmaceuticals Inc stock and bought 153,034,058 units worth $217,351,881 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, AVEO Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $9,488,415. The most recent stock trade was executed by Michael P Bailey on 20 December 2022, trading 276,746 units of AVEO stock currently worth $1,248,124.
What does AVEO Pharmaceuticals Inc do?
AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.
What does AVEO Pharmaceuticals Inc's logo look like?
Complete history of Equity I stock trades at AVEO Pharmaceuticals Inc
AVEO Pharmaceuticals Inc executives and stock owners
AVEO Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Michael Bailey,
President, Chief Executive Officer, Director -
Michael P. Bailey,
CEO, Pres & Director -
Karuna Rubin,
Senior Vice President, General Counsel -
Michael Needle,
Chief Medical Officer -
Kenneth Bate,
Lead Independent Director -
Gregory Mayes,
Independent Director -
Anthony Evnin,
Independent Director -
Robert Young,
Independent Director -
Scarlett Spring,
Independent Director -
David Pitts,
IR Contact Officer -
Erick Lucera,
Chief Financial Officer -
Dr. Sinai Davis M.D.,
VP & Global Head of Pharmacovigilance -
Jeb Ledell,
Chief Operating Officer -
Erick Lucera CFA, CPA,
Chief Financial Officer -
Michael Ferraresso,
Chief Commercial Officer -
Catherine DeRose,
VP of HR -
David Crist,
VP of Sales -
Kevin Peacock,
VP of Marketing -
Danielle Holland,
Sr. Corp. Counsel & Corp. Sec. -
Dr. Emile Farhan,
Sr. VP of Technical Operations & Quality Assurance -
Lisa M. Bruneau,
VP of Financial Accounting & Reporting and Treasurer -
Erick Lucera CPA, CFA,
Chief Financial Officer -
Scott D Sandell,
10% owner -
Peter W. Sonsini,
10% owner -
Joshua Makower,
10% owner -
Equity Opportunities Fund I...,
-
Henri A Termeer,
Director -
Keith S Ehrlich,
Chief Financial Officer -
Forest Baskett,
10% owner -
Ravi Viswanathan,
10% owner -
Jon Sakoda,
10% owner -
David M Mott,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Peter J Barris,
10% owner -
Equity Opportunities Fund I...,
-
Matthew D Dallas,
VP, Finance -
Nikhil Mehta,
See Remarks -
John Johnson,
Director -
Chetan Puttagunta,
10% owner -
Mohamad Makhzoumi,
10% owner -
Kevin Joseph Cullen,
Director -
Bioventures Ii Qp Lpmpm Bio...,
-
Douglas G. Cole,
Director -
David Brannon Johnston,
Chief Financial Officer -
Jeno Gyuris,
SVP, Head of Research -
Russell C Hirsch,
Director -
Kenneth E Weg,
Director -
Elan Ezickson,
Chief Business Officer -
William Slichenmyer,
Chief Medical Officer -
Nicholas Galakatos,
Director -
Ronald A De Pinho,
Director -
Joseph Vittiglio,
SVP & General Counsel -
Robert S Epstein,
Director -
Murray O. Robinson,
SVP, Translational Medicine -
Raju S Kucherlapati,
Director -
Mary Ellen Jones,
SVP, Human Resources -
Ngoc Tuan Ha,
Chief Executive Officer -
Corinne Epperly,
Director -
Michael Ferraresso,
Chief Commercial Officer -
Jebediah Ledell,
Chief Operating Officer -
Enterprise Associates 15, L...,
10% owner -
Equity Opportunities Fund I...,
10% owner -
Partners 15, L.P.Nea 15 Gp,...,